85. Idiopathic interstitial pneumonia Clinical trials / Disease details


Clinical trials : 627 Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-006278-22-NL
(EUCTR)
29/08/202201/06/2022A study to find out if orvepitant is safe to use and reduces the severity of cough in patients with idiopathic pulmonary fibrosisA DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, TWO PERIOD CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORVEPITANT IN CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS Chronic cough in patients with idiopathic pulmonary fibrosis
MedDRA version: 21.1;Level: LLT;Classification code 10066656;Term: Chronic cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Orvepitant
INN or Proposed INN: ORVEPITANT
Product Name: Orvepitant
INN or Proposed INN: ORVEPITANT
NeRRe Therapeutics LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
108Phase 2United States;Netherlands;United Kingdom
2NCT05185089
(ClinicalTrials.gov)
August 1, 202223/12/2021Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary FibrosisA Double-Blind, Randomised, Placebo Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients With Idiopathic Pulmonary FibrosisCough;Idiopathic Pulmonary FibrosisDrug: Orvepitant Maleate;Drug: PlaceboNerre Therapeutics Ltd.Pharm-Olam InternationalRecruiting40 YearsN/AAll88Phase 2United States;Netherlands;United Kingdom